Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-04-24
2003-02-25
Gerstl, Robert (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S214000
Reexamination Certificate
active
06525081
ABSTRACT:
TECHNICAL FIELD
The present invention relates to novel benzylidene derivatives, and an antirheumatic agent, an osteoclast formation inhibiting agent, a nitrogen monoxide production inhibiting agent, and a transcription factor NF&kgr;B suppressing agent comprising said benzylidene derivative as an active ingredient. The present invention further relates to a method for the prevention and/or treatment of rheumatic diseases, a method for the inhibition of osteoclast formation, a method for the inhibition of nitrogen monoxide production, and a method for the suppression of transcription factor NF&kgr;B.
BACKGROUND ART
Rheumatic disease is a systemic inflammatory disease involving a functional abnormality accompanied by swellings and pains in arthrosis as the primary symptom. The number of the patients in Japan is estimated as more than about 600 thousands (morbidity: about 0.5% of the Japanese population), and many of these patients are females of middle to advanced age. Although the development of this disease has not yet been well elucidated, it is believed to be a trigger for this disease that an immunological abnormality occurs for some reason, the autoimmune response is accelerated, and an activated macrophage, neutrophil, T-cell and the like are infiltrated to inflammatory focus. Then, these cells receive an inflammatory stimulus to produce various inflammatory mediators such as IL-1, IL-6, THF-&agr;, nitrogen monoxide (NO) and prostaglandin E
2
(PGE
2
). The mediators then induce a cell adhesion factor, collagenase, protease and the like, which cause swelling and pain and accelerate the destruction of articular cartilage and bone.
According to the recent findings, activation of NF&kgr;B due to inflammatory stimulation induces cyclooxygenase-2 (COX-2) and inductive nitrogen monoxide synthase (i-NOS), and also accelerates an expression of cytokines. Cytokines and NO produced in the inflammatory focus activate NF&kgr;B.
As a result, it is believed that the production of inflammatory mediators is enhanced in the inflammatory focus and the chronic inflammation pathology accompanied by the tissue destruction is thus developed. NO is also associated with the activation of COX-2 and accelerates production of PGE
2
.
Certain benzylidene compounds exhibit an anti-inflammatory effect, and therefore, they are currently used the treatment of rheumatic diseases as a nonsteroidal anti-inflammatory drug (NSAID), for the purpose of suppressing pains and swellings. However, the use of such nonsteroidal anti-inflammatory drug is a mere symptomatic therapy for the suppression of pains and swellings due to rheumatic diseases and is not curable for the disease itself.
On the other hand, antirheumatic agents (disease-modifying antirheumatic drug) inhibit the progression of rheumatic pathology and they are used in a radical therapy for the disease. The compounds of the present invention have been found to inhibit articular bone destruction, a rheumatic pathology, in a rheumatic model animal (NZB/KN) to which a nonsteroidal anti-inflammatory drug is not effective. Thus, the compounds have been found to be effective in a radical therapy of rheumatic diseases via a different mechanism from that of anti-inflammatory agents.
Combination use of a disease-modifying antirheumatic drug (DMARD) such as immunosuppressants or immunomodulators and a nonsteroidal anti-inflammatory drug (NSAID) is often conducted in the treatment of chronic arthritis such as rheumatoid arthritis. However, these drug have drawbacks in that the former may often cause serious side effects such as blood disorder, and the latter may cause gastrointestinal disorder due to prolonged administration. Accordingly, a drug which possesses the DMARD and NSAID effects but less side effects would be very useful as a therapeutic agent for rheumatoid arthritis.
SUMMARY OF THE INVENTION
The present inventors have found that particular benzylidene derivatives, i.e. the compounds of formula I:
wherein
R
1
is hydrogen, lower alkyl, lower alkoxy, hydroxy lower alkyl, or carboxy lower alkyl and R
4
is hydroxy; or
R
1
and R
4
taken together form —CR
5
R
6
—(CH
2
)
m
—O— or —CR
5
R
6
—(CH
2
)
p
CH(OH)—O—
wherein m is an integer of 1 to 3;
p is an integer of 0 to 2; and
R5 and R6 are each independently hydrogen, lower alkyl, lower alkoxy, or hydroxy lower alkyl;
R
2
is hydrogen, lower alkyl, lower alkoxy, hydroxy lower alkyl, or carboxy lower alkyl; and
R
3
is hydrogen, lower alkyl, cycloalkyl, lower alkoxy, arylalkyloxy, heteroarylalkyloxy, lower alkylcarbonyl, arylcarbonyl, substituted or unsubstituted carbamoyl or the group represented by the formula:
—(CH
2
)
n
—Q
wherein Q is hydroxy, substituted or unsubstituted amino, aryl, heteroaryl, hydroxycarbonyl or lower alkyloxycarbonyl; and
n is an integer of 0 to 3
exhibit not only anti-inflammatory effect but also antirheumatic effect. The present invention has been accomplished on the basis of the above finding.
The present inventors also have found that the above compounds inhibit enhanced formation of osteoclast caused by PGE
2
.
Also, the above compounds have been found to suppress an inducible nitrogen monoxide synthase (i-NOS) to inhibit NO production.
Further, the above compounds have been found to posses suppressive activity on a transcription factor NF&kgr;B.
Accordingly, the present invention provides novel uses of such derivatives as an antirheumatic agent, an osteoclast formation inhibiting agent, a nitrogen monoxide production inhibiting agent, and a transcription factor NF&kgr;B suppressing agent.
Thus, the present invention provides an antirheumatic agent comprising a compound of formula I or pharmaceutically acceptable salt or hydrate thereof as an active ingredient.
The present invention also provides an osteoclast formation inhibiting agent comprising a compound of formula I or pharmaceutically acceptable salt or hydrate thereof as an active ingredient.
The present invention further provides a nitrogen monoxide production inhibiting agent comprising a compound of formula I or pharmaceutically acceptable salt or hydrate thereof as an active ingredient.
The present invention yet further provides a transcription factor NF&kgr;B suppressing agent comprising a compound of formula I or pharmaceutically acceptable salt or hydrate thereof as an active ingredient.
The compounds of the formula I wherein R
1
and R
2
are both t-butyl, more preferably R
1
and R
2
are both t-butyl and R
4
is hydroxy, more preferably R
1
and R
2
are both t-butyl, R
3
is lower alkyl and R
4
is hydroxy, much more preferably R
1
and R
2
are both t-butyl, R
3
is ethyl and R
4
is hydroxy, are preferred antirheumatic agents, osteoclast formation inhibiting agents, nitrogen monoxide production inhibiting agents and transcription factor NF&kgr;B suppressing agents.
The present invention further provides use of the compounds of formula I for the manufacture of anti-rheumatic agent.
Also, the present invention provides use of the compounds of formula I for the manufacture of osteoclast formation inhibiting agent.
Further, the present invention provides use of the compounds of formula I for the manufacture of nitrogen monoxide production inhibiting agent.
Yet further, the present invention provides use of the compounds of formula I for the manufacture of transcription factor NF&kgr;B suppressing agent.
The present invention further provides a method for the prevention and/or treatment of rheumatoid arthritis which comprises administering an effective amount of a compound of formula I to mammals in need thereof.
Also, the present invention provides a method for the inhibition of osteoclast formation which comprises administering an effective amount of a compound of formula I to mammals in need thereof.
Further, the present invention provides a method for the inhibition of nitrogen monoxide production which comprises administering an effective amount of a compound of formula I to mammals in need thereof.
Yet further, the present invention provides a method for the suppression of transcription factor NF&
Hanasaki Kohji
Jyoyama Hirokuni
Kakudo Shinji
Koizumi Kenzo
Matsumoto Saichi
Gerstl Robert
Shionogi & Co. Ltd.
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Antirheumatic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antirheumatic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antirheumatic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3166204